Ronald K Chang

USPTO Granted Patents = 11 (Patent Applications = 4)

CIPO Patents = 1

EPO Patents = 11 (Patent Applications = 15)

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 31(Granted Patents)

Location History:

West Point, PA (US) (2014)
Oreland, PA (US) (2012 - 2017)

Company Filing History:

11 out of 2,405

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 2012-2017

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9718818 - Compounds inhibiting leucine-rich repeat kinase enzyme activity (2017-08-01),

2. 9315475 - HIV protease inhibitors (2016-04-19),

3. 9260418 - Pyranyl aryl methyl benzoquinolinone M1 receptor positive allosteric modulators (2016-02-16),

4. 8846702 - Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators (2014-09-30),

5. 8754220 - Quinolizidinone carboxamide M1 receptor positive allosteric modulators (2014-06-17),

6. 8664387 - Pyridoquinazolinone M1 receptor positive allosteric modulators (2014-03-04),

7. 8664234 - Dihydrobenzoquinazolinone M1 receptor positive allosteric modulators (2014-03-04),

8. 8288409 - Quinolizidinone M1 receptor positive allosteric modulators (2012-10-16),

9. 8273737 - Quinolizidinone M1 receptor positive allosteric modulators (2012-09-25),

10. 8258135 - Quinolizidinone M1 receptor positive allosteric modulators (2012-09-04),

11. 8173672 - Quinolizidinone M1 receptor positive allosteric modulators (2012-05-08),

Title: Inventor Spotlight: Ronald K. Chang

Introduction

Ronald K. Chang, an innovative inventor hailing from Oreland, PA, is recognized for his remarkable contributions to the field of pharmaceuticals. With a total of 11 patents to his name, Chang has dedicated his work to developing compounds that address significant health challenges facing society today.

Latest Patents

Among his latest patents, Chang has developed compounds that inhibit the activity of the leucine-rich repeat kinase enzyme. This invention focuses on azaindazole compounds that serve as potent inhibitors of the LRRK2 kinase, which plays a crucial role in conditions such as Parkinson's disease. His research also leads to the creation of pharmaceutical compositions that incorporate these compounds, offering avenues for treatment and prevention.

Additionally, Ronald Chang has made strides in the fight against HIV with his development of HIV protease inhibitors. The compounds he has formulated include those that are metabolized in vivo to become effective HIV protease inhibitors. These inventions are vital in the prophylaxis and treatment of HIV infections and serve as essential components in pharmaceutical compositions that may include other antivirals and immunomodulators.

Career Highlights

Throughout his career, Ronald K. Chang has worked with industry leaders such as Merck Sharp & Dohme Corporation and Merck Canada Inc. These experiences have significantly contributed to his knowledge and expertise in pharmaceutical innovation, allowing him to develop groundbreaking inventions that have the potential to save lives.

Collaborations

Chang has collaborated with notable professionals in his field, including Scott D. Kuduk and Thomas J. Greshock. These partnerships have fostered an environment of shared knowledge and creativity, leading to fruitful innovations aimed at improving health outcomes.

Conclusion

Ronald K. Chang's inventive spirit and dedication to addressing pressing health issues are reflected in his numerous patents and collaborations. His work stands as a testament to the power of innovation in transforming the future of medicine and improving the quality of life for individuals affected by debilitating diseases.

This text is generated by artificial intelligence and may not be accurate.